This past week, a number of Democrats in the House and Senate introduced the Improving Access to Affordable Prescription Drugs Act. It covers a lot of ground: Title I, Transparency; Title II, Access and Affordability; Title III, Innovation; Title IV, Choice and Competition.
In other words, it aggregates a bunch of ideas that have been circulating around how to address pharma access and cost issues, e.g.: permitting Medicare to negotiate prices, allowing HHS OIG to investigate price spikes (hi Martin Shkreli!), requiring pharma companies to report R&D investment, drug reimportation, shifting duals from Medicare back to Medicaid drug coverage, a $2 billion innovation prize to encourage novel antibiotic development, and more.
A brief summary can be found here: franken.senate.gov/files/lette...
For an excellent analysis, I recommend Rachel Sachs' assessment of the bill, here: blogs.harvard.edu/billofhealth...
On the merits, what are the strongest/weakest ideas in this bill? More importantly, what is politically feasible?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.